CC

Clinical Cancer Research

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; immunotherapy; gene therapy; diagnostic biomarkers; innovative imaging, and clinical genetics.

Looking to publish in Clinical Cancer Research? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Oncology
Impact Factor 10.2
Quartile Q1
Open Access Type Closed
ISSN 1078-0432
eISSN 1557-3265
Invitation Only No
Cost Range Publication involves a base publication fee and an additional fee for each display item; authors may apply for a waiver of the fixed publication fee if no financial support exists.

Submission Instructions

Clinical Cancer Research accepts the following article types. Click on an article type to view submission instructions.

Original Research Articles

Cover Letter Cover letter is not required but authors are strongly encouraged to upload one. Any use of AI to produce new text, images, or other material for the manuscript must be described in detail in the cover letter.
Abstract An abstract is required.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript should include Title Page, a 150-word translational relevance statement on a separate page before the abstract, Abstract, Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Methods. Manuscript must include a 150-word translational relevance statement, a conflict of interest disclosure on the title page, an AI-use declaration in the acknowledgments and manuscript as applicable, a Data Availability Statement, and a Code Availability Statement when custom code was used.
References References must be numbered in order of first mention in the text, cited in the text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors.
Figures & Tables For initial submission, figures should be on the same page as the legend either at the end of the manuscript file or embedded in the text near the figure callout, and supplementary data should be uploaded separately. Each figure must have a legend, figures and tables must be cited and numbered in the order they appear, and figure legends must include the number of technical and biological replicates.
Reformat to Clinical Cancer Research using Livewrite Premium

Review Manuscript

Cover Letter Cover letter is strongly encouraged but not required. Cover letters for review articles are not required at submission, but presubmission inquiries should include an outline or draft and a list of key references if available.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. The manuscript should include Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Materials and Methods. The title page must include the word count, total number of figures and tables, and a conflict of interest statement, and any use of generative artificial intelligence or human-assisted editing services must be declared in the acknowledgments or other appropriate manuscript section.
References References must be numbered in order of first mention in the text, cited in the text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors.
Figures & Tables For initial submission, figures should appear on the same page as the legend either embedded near the figure callout or placed at the end of the manuscript file, and authors are strongly encouraged to upload a single manuscript file containing the text and all display items. Each figure must be numbered in text order and accompanied by a legend, and every table must have a descriptive title and enough explanatory information to be understood without reference to the text.
Reformat to Clinical Cancer Research using Livewrite Premium

Meta-Analysis

Cover Letter Cover letter is strongly encouraged but not required. Any use of AI to produce new text, images, or other material for the manuscript must be described in detail in the cover letter.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. The manuscript must include a 150-word statement of translational relevance on a page between the title page and abstract. A detailed conflict of interest disclosure statement must appear on the title page, and any use of generative artificial intelligence or human-assisted editing services must be declared in the acknowledgments section.
References References must be numbered in the order of first mention in the text, with up to 6 authors listed in full and more than 6 authors abbreviated after the first 6 with "et al.".
Figures & Tables For initial submission, figures should be embedded on the same page as the legend either near the figure callout or at the end of the manuscript file. Each table must be numbered with a descriptive title, and each figure must be numbered in text order and accompanied by a legend that defines the figure and any panel labels.
Reformat to Clinical Cancer Research using Livewrite Premium

Systematic Reviews

Cover Letter Cover letter is strongly encouraged but not required. Cover letter must describe any use of AI to produce new text, images, or other material and explain how any associated manuscript is related to the submission.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript should include Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Materials and Methods, and Systematic Reviews must follow PRISMA. A 150-word translational relevance statement must appear on a page between the title page and abstract, AI assistance in manuscript preparation must be declared in the acknowledgments, and the title page must include the word count, total number of figures and tables, and a conflict of interest disclosure statement.
References References must be numbered in order of first mention in the text, cited in the text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors or all authors when there are 6 or fewer.
Figures & Tables For initial submission, figures should be placed on the same page as the legend either at the end of the manuscript file or embedded near the figure callout, and authors are strongly encouraged to upload a single manuscript file containing the main text and all display items. Each figure must be numbered in text order and accompanied by a legend with a short title sentence and description, including panel labels and descriptions when applicable, while every table must be numbered in Arabic numerals and include a descriptive title.
Reformat to Clinical Cancer Research using Livewrite Premium

Clinical Trials

Cover Letter Cover letter is strongly encouraged rather than required. Cover letter must describe how any associated manuscript is related to the submission, disclose any restrictions on availability of manuscript components, and detail any use of AI to produce new text, images, or other material.
Abstract Abstract is required.
Manuscript Manuscript should include the standard sections of title page, abstract, Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Materials and Methods, with a 150-word translational relevance statement placed between the title page and abstract. Manuscript must include a detailed conflict of interest disclosure on the title page, the trial registration number when applicable, an acknowledgments disclosure of any generative AI or human-assisted editing help, and a supplementary table describing cancer background and study population representativeness including patient characteristics such as sex or gender, age, race or ethnicity, and geography.
References References must be numbered in order of first mention in the text, cited in text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors or all authors when there are 6 or fewer.
Figures & Tables For initial submission, figures should be embedded in the manuscript near the figure callout or placed at the end on the same page as the legend, while supplementary data must be uploaded separately. Each figure must be numbered in text order and accompanied by a legend, and Clinical Trials must also include a supplementary table covering cancer background and the representativeness of the study population.
Reformat to Clinical Cancer Research using Livewrite Premium

Recent Publications

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Attaya Suvannasankha, Mengying Li, Omonefe Omofuma, Christian Hampp, Matthew Phelan, Alexander Breskin, Ping Shao, Tito Roccia, Nandita Mukherjee, Anju Shrestha, Daniel Lee, Jacob Glass, Glenn S. Kroog, Karen Rodriguez Lorenc

10.1158/1078-0432.ccr-25-4068
View Publication

The biology of hypomorphic TP53 variants and implications for clinical management

Renyta Moses, Jacquelyn Powers, Alison S. Levine, Judy E. Garber, Suzanne P. MacFarland, Huma Q. Rana, Maureen E. Murphy, Kara N. Maxwell

10.1158/1078-0432.ccr-25-4543
View Publication

Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses

Lea Ruge, Felix John, Malte Verheyen, Richard Riedel, Sebastian Michels, Lucia Nogova, Heather Scharpenseel, Rieke Fischer, Sofia Stilianakis, Janna Siemanowski-Hrach, Jana Fassunke, Anna Rasokat, Anna Kron, Marvin Kirsch, Monika Serke, Jutta Kappes, Kato Kambartel, Udo Siebolts, Sabine Merkelbach-Bruse, Reinhard Büttner, Jürgen Wolf, Matthias Scheffler

10.1158/1078-0432.ccr-26-0133
View Publication

TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trial

Cheng Xu, Si-Yang Wang, Man Nie, Kun-Yu Yang, Xin-Qiong Huang, Song Qu, Hui Chen, Liang-Fang Shen, Jing Huang, Fan Zhang, Ying-Peng Peng, Liang-Liang Shi, Xiao-Hua Hong, Zhan-Jie Zhang, Ling-Long Tang, Ling Guo, Pu-Yun Ouyang, Jian-Ming Gao, Yan-Ping Mao, Ying Huang, Rui Guo, Li-Zhi Liu, Li Tian, Hao-Jiang Li, Ji-bin Li, Jun Ma, Yi Xia, Qing-Qing Cai

10.1158/1078-0432.ccr-26-0347
View Publication

A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastoma

Hui K. Gan, Lawrence Cher, Po-ling Inglis, Zarnie Lwin, Ashray Gunjur, Adi Balasubramanian, Andrew Schmidt, Christian W. Wichmann, Nancy Guo, Sze Ting Lee, Paul Thomas, Fiona E. Scott, Chloe Shard, Kate Fluck, Nicole Coombs, Jodie Palmer, Mary E. Vail, Stacey Allen, Ashwini Patil, Bhupinder Pal, Graeme J. O'Keefe, Sylvia J. Gong, Gaia Ninatti, Bryan W. Day, Guillermo A. Gomez, Peter W. Janes, Andrew M. Scott

10.1158/1078-0432.ccr-25-3608
View Publication

Frequently asked questions

How long does it take to publish?

AACR member authors may receive a full refund of the journal publication fee if the time from completion of submission to the first decision after external peer review exceeds 60 days.

Reformat to Clinical Cancer Research using Livewrite Premium

Is a cover letter required?

Authors are strongly encouraged to upload a cover letter for initial submission.

Reformat to Clinical Cancer Research using Livewrite Premium

What are the publication costs?

Publication involves a base publication fee and an additional fee for each display item; authors may apply for a waiver of the fixed publication fee if no financial support exists.

Reformat to Clinical Cancer Research using Livewrite Premium

Research Topics

Cancer Genomics and Diagnostics Cancer Immunotherapy and Biomarkers Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Immunotherapy and Immune Responses Lung Cancer Treatments and Mutations Breast Cancer Treatment Studies CAR-T cell therapy research Cancer, Hypoxia, and Metabolism Cancer-related Molecular Pathways Cancer Cells and Metastasis Epigenetics and DNA Methylation PARP inhibition in cancer therapy Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology RNA modifications and cancer Prostate Cancer Treatment and Research Cancer Research and Treatments Monoclonal and Polyclonal Antibodies Research Pancreatic and Hepatic Oncology Research Ovarian cancer diagnosis and treatment PI3K/AKT/mTOR signaling in cancer Genetic factors in colorectal cancer Immune Cell Function and Interaction Lung Cancer Research Studies

Related Journals

CN
Cancer Nanotechnology BioMed Central
Le
Leukemia Springer Nature
JO
Journal of Experimental & Clinical Cancer Research BioMed Central
BE
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer Elsevier BV
JC
JNCI Cancer Spectrum Oxford University Press
JO
Journal of Chemotherapy Taylor & Francis